Man­u­fac­tur­ing is­sues hold back dis­tri­b­u­tion of over­dose in­jec­tion; San Diego biotech triples foot­print

In April, Pfiz­er was forced to stop pro­duc­tion of the in­jectable opi­oid an­ti­dote nalox­one, af­ter a man­u­fac­tur­ing is­sue. Now, a short­age has raised the alarm …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER